Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Impact of sildenafil on survival of patients with Eisenmenger syndrome.

Sun YJ, Yang T, Zeng WJ, Gu Q, Ni XH, Zhao ZH, Liu ZH, Xiong CM, He JG.

J Clin Pharmacol. 2013 Jun;53(6):611-8. doi: 10.1002/jcph.78. Epub 2013 Mar 30.

PMID:
23553708
2.

Impact of sildenafil on survival of patients with idiopathic pulmonary arterial hypertension.

Zeng WJ, Sun YJ, Gu Q, Xiong CM, Li JJ, He JG.

J Clin Pharmacol. 2012 Sep;52(9):1357-64. doi: 10.1177/0091270011418656. Epub 2011 Sep 28.

PMID:
21956607
3.

Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study.

Garg N, Tripathy N, Sinha N.

Cardiol Young. 2011 Dec;21(6):631-8. doi: 10.1017/S1047951111000497. Epub 2011 Jun 8.

PMID:
21729508
4.

Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study.

Zhang ZN, Jiang X, Zhang R, Li XL, Wu BX, Zhao QH, Wang Y, Dai LZ, Pan L, Gomberg-Maitland M, Jing ZC.

Heart. 2011 Nov;97(22):1876-81. doi: 10.1136/heartjnl-2011-300344. Epub 2011 Sep 21.

PMID:
21948962
5.

Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.

D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.

Int J Cardiol. 2012 Mar 22;155(3):378-82. doi: 10.1016/j.ijcard.2010.10.051. Epub 2010 Nov 16.

PMID:
21081251
6.

Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy.

Tay EL, Papaphylactou M, Diller GP, Alonso-Gonzalez R, Inuzuka R, Giannakoulas G, Harries C, Wort SJ, Swan L, Dimopoulos K, Gatzoulis MA.

Int J Cardiol. 2011 Jun 16;149(3):372-6. doi: 10.1016/j.ijcard.2010.02.020. Epub 2010 Mar 20.

PMID:
20304507
7.

Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome.

Yang-Ting S, Aboulhosn J, Sun XG, Child JS, Sietsema KE.

Congenit Heart Dis. 2011 Mar-Apr;6(2):139-46. doi: 10.1111/j.1747-0803.2011.00490.x. Epub 2011 Mar 21.

PMID:
21418531
8.

Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension.

Chau EM, Fan KY, Chow WH.

Int J Cardiol. 2007 Sep 3;120(3):301-5. Epub 2006 Dec 14.

PMID:
17174418
9.

Dyspnea in Eisenmenger syndrome and its amelioration by sildenafil: role of J receptors.

Anand A, Srivastava N, Barwad P, Ramakrishnan S, Roy A, Bhargava B.

Int J Cardiol. 2014 Jul 1;174(3):574-8. doi: 10.1016/j.ijcard.2014.04.131. Epub 2014 Apr 21.

PMID:
24820738
10.

The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension.

Xu XQ, Jing ZC, Zhang JH, Wu Y, Wang Y, Jiang X, Wang ZX, Sun YG, Pu JL, Yang YJ.

Hypertens Res. 2009 Oct;32(10):911-5. doi: 10.1038/hr.2009.113. Epub 2009 Jul 31.

PMID:
19644505
11.

Scheduled perioperative switch from oral sildenafil to intravenous epoprostenol in a patient with Eisenmenger syndrome undergoing a sigmoidectomy.

Moriyama K, Uzawa K, Iijima T, Kotani M, Moriyama K, Ohashi Y, Satoh T, Yorozu T.

J Clin Anesth. 2012 Sep;24(6):487-9. doi: 10.1016/j.jclinane.2012.02.005. Epub 2012 Jul 2.

PMID:
22762976
12.

Effects of sildenafil citrate on five dogs with Eisenmenger's syndrome.

Nakamura K, Yamasaki M, Ohta H, Sasaki N, Murakami M, Bandula Kumara WR, Takiguchi M.

J Small Anim Pract. 2011 Nov;52(11):595-8. doi: 10.1111/j.1748-5827.2011.01127.x. Epub 2011 Oct 10.

PMID:
21985577
13.

[Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].

Raposo-Sonnenfeld I, Otero-González I, Blanco-Aparicio M, Ferrer-Barba A, Medrano-López C.

Rev Esp Cardiol. 2007 Apr;60(4):366-72. Spanish.

14.
15.

Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.

Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.

J Heart Lung Transplant. 2007 Apr;26(4):363-9. Epub 2007 Mar 2.

PMID:
17403478
16.

Sildenafil use in patients with the Eisenmenger syndrome.

Rosenthal E.

Circulation. 2004 Apr 27;109(16):e197; author reply e197. No abstract available.

17.

Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.

Garg N, Sharma MK, Sinha N.

Int J Cardiol. 2007 Sep 3;120(3):306-13. Epub 2006 Dec 15.

PMID:
17174417
18.

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.

Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F.

J Am Coll Cardiol. 2003 Jul 2;42(1):158-64.

19.

Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.

Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.

Circulation. 2003 Oct 28;108(17):2066-9. Epub 2003 Oct 20.

20.

Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.

Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.

J Heart Lung Transplant. 2007 Nov;26(11):1079-83. Epub 2007 Oct 24.

PMID:
18022071

Supplemental Content

Support Center